Evofem biosciences, inc. (EVFM)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating expenses:
Research and development

4,247

3,432

5,663

5,246

7,889

9,772

9,851

11,833

11,959

11,216

6,263

4,078

1,982

9,201

964

1,428

3,260

7,027

15,211

7,469

4,700

1,916

942

932

1,383

Selling and marketing

7,855

-

-

-

1,118

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

7,142

10,558

8,634

6,695

4,625

5,209

8,582

11,409

9,027

4,130

2,807

2,280

2,931

10,565

905

1,091

2,520

2,203

1,768

1,729

1,937

1,341

922

1,050

1,101

Total operating expenses

19,244

12,872

14,297

11,941

13,632

14,981

18,433

23,242

20,986

15,346

9,070

6,358

4,913

24,471

1,870

2,519

5,781

9,231

16,980

9,199

6,637

3,257

1,865

1,982

2,484

Loss from operations

-19,244

-12,872

-14,297

-11,941

-13,632

-14,981

-18,433

-23,242

-20,986

-15,346

-9,070

-6,358

-4,913

-24,471

-1,870

-2,519

-5,781

-9,231

-16,980

-9,199

-6,637

-3,257

-1,865

-1,982

-2,484

Other income (expense):
Interest income

102

120

212

108

18

30

35

32

30

33

32

32

31

26

13

16

19

5

6

6

7

4

1

0

0

Other expense

4

-

-

-

14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

-

-

287

-7

-

-30

-33

-32

-50

-34

-42

64

-34

-

-

-

-

-

-

-

-

-

-

-

-

Loss on issuance of Series D redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

2,782

5,740

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss on issuance of warrants

-

-

0

0

-

0

0

0

47,920

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on issuance of Purchase Rights

-

-

0

674

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

506

154

265

289

287

285

271

212

132

26

4

Fair Value Adjustment of Warrants

0

0

0

3,315

4,440

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-568

2,044

271

-886

Change in fair value of Purchase Rights

-

-

0

19,617

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of Series D 2X liquidation preference

-

-

0

0

-

0

0

0

-130

-1,364

-59,211

-250

-350

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense), net

98

155

499

-23,505

-4,436

0

2

0

-48,070

-4,147

-64,961

-154

-353

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income tax

-19,146

-12,717

-13,798

-35,446

-18,068

-14,981

-18,431

-23,242

-69,056

-19,493

-74,031

-6,512

-5,266

-

-

-

-

-

-

-

-

-

-

-

-

Income tax expense

0

0

0

4

0

-

0

2

-

0

0

0

3

-

-

-

-

-

-

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-19,146

-12,717

-13,798

-35,450

-18,068

-14,981

-18,431

-23,244

-69,056

-19,493

-74,031

-6,512

-5,269

-55,620

-2,362

-2,657

-6,026

-9,515

-17,262

-9,477

-6,902

-2,896

-4,040

-2,279

-1,602

Accretion of Series D redeemable convertible preferred stock dividends

-

-

0

0

-

0

0

0

66

1,178

1,054

897

888

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-13,798

-35,450

-

-14,981

-18,431

-23,244

-69,122

-20,671

-75,085

-7,409

-6,157

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basic and diluted (in dollars per share)

-0.40

-0.05

-0.30

-0.97

-0.67

0.70

-0.71

-1.11

-4.62

-10.55

-38.31

-3.78

-3.14

-0.09

-0.17

-0.19

-0.44

-16.46

-1.26

-0.69

-0.50

9.08

-7.31

-4.13

-3.00

Weighted-average shares used to compute net loss per share, basic and diluted (in shares)

48,195

51,058

46,239

36,732

26,883

25,980

25,778

20,868

14,974

1,959

1,959

1,959

1,959

264,829

13,816

13,800

13,757

-31,919

13,702

13,676

13,671

6,431

552

552

533